NovaBay Pharmaceuticals, Inc. (AMEX: NBY) has focused their efforts on developing innovative product candidates that target the treatment or prevention of a broad array of infections in hospital and community environments. Because of the rapid increase in infectious microbes that are resistant to current drugs, many of these infections have become increasingly difficult to treat. Vitro and in vivo tests have proven that the company’s compounds kill a broad range of bacteria, viruses and other infection causing microbes, even those that are resistant to multiple antibiotics. For further information, visit the Company’s web site at www.novabaypharma.com.
- 18 years ago
QualityStocks
NovaBay Pharmaceuticals, Inc. (AMEX: NBY)
Tags Rodman & Renshaw
Related Post
-
Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
In the United States alone, close to one million people are living with MS, with…
-
Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step
California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…
-
Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership
The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…